By Dean Seal
Shares of Inozyme Pharma soared to near the $4 per-share price BioMarin Pharmaceutical said it would pay for the company.
The stock more than doubled to $3.95 in late morning trading on Friday. It closed the market session on Friday at $1.42.
BioMarin said Friday morning that it has agreed to buy Inozyme for $4 a share, or about $280 million in cash.
The deal has been approved by the directors of both companies and is expected to close in the third quarter.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 16, 2025 11:44 ET (15:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.